PREININGEROVA, Jana Lizrova, Ulf BAUMHACKL, Tunde CSEPANY, Adam CZAPLINSKI, Florian DEISENHAMMER, Tobias DERFUSS, Tanja H. FABJAN, Franz FAZEKAS, Siegrid FUCHS, Eva HAVRDOVA, Alenka Horvath LEDINEK, Zsolt ILLES, Sasa Sega JAZBEC, Eleonora KLIMOVA, Samuel KOMOLY, Egon KURCA, Michael LINNEBANK, Lubomir LISY, Jan MARES, Lubica PROCHAZKOVA, Rozsa CSILLA, Jarmila SZILASIOVA, Pavel ŠTOURAČ, Radomir TALAB, Peter TURCANI, Marta VACHOVA, Laszlo VECSEI, David VODUSEK, Olga ZAPLETALOVA and Thomas BERGER. Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS). CNS NEUROSCIENCE &THERAPEUTICS. HOBOKEN: WILEY-BLACKWELL, 2013, vol. 19, No 5, p. 302-306. ISSN 1755-5930. Available from: https://dx.doi.org/10.1111/cns.12101.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)
Authors PREININGEROVA, Jana Lizrova, Ulf BAUMHACKL, Tunde CSEPANY, Adam CZAPLINSKI, Florian DEISENHAMMER, Tobias DERFUSS, Tanja H. FABJAN, Franz FAZEKAS, Siegrid FUCHS, Eva HAVRDOVA, Alenka Horvath LEDINEK, Zsolt ILLES, Sasa Sega JAZBEC, Eleonora KLIMOVA, Samuel KOMOLY, Egon KURCA, Michael LINNEBANK, Lubomir LISY, Jan MARES, Lubica PROCHAZKOVA, Rozsa CSILLA, Jarmila SZILASIOVA, Pavel ŠTOURAČ, Radomir TALAB, Peter TURCANI, Marta VACHOVA, Laszlo VECSEI, David VODUSEK, Olga ZAPLETALOVA and Thomas BERGER.
Edition CNS NEUROSCIENCE &THERAPEUTICS, HOBOKEN, WILEY-BLACKWELL, 2013, 1755-5930.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.784
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/cns.12101
UT WoS 000318112800003
Keywords in English Aminopyridines; Fampridine; Multiple sclerosis; Walking
Tags ne MU
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 20/1/2014 14:27.
Abstract
Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
PrintDisplayed: 19/7/2024 22:26